Dergiler / Bezmiâlem Science / 2020 / Cilt: 8 - Sayı: 3

COVID-19: Ivermectin; Molecular Mechanisms, Limitations, Suggestions

COVİD-19: İvermektin; Moleküler Mekanizmalar, Sınırlılıklar, Öneriler

Sayfa
39–43
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this review, the applicability, risks, and possible molecular mechanisms of ivermectin, which is suggested to be an effective treatment option, are discussed within the framework of the pharmacokinetic and toxicokinetic properties of the drug.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:To date, no effective treatment has been found against coronaviruses (CoVs), which have re-emerged with severe acute respiratory syndrome CoV-2 (SARS-CoV-2) and have a high potential for disease in humans as well as domestic and wild animal species.
📊
Temel Bulgular & Veri:The investigation of treatment options to combat this virus, which has a pandemic character with its high morbidity and mortality rate, is a multidisciplinary research subject.
💡
Sonuç & Katkı:In this review, the applicability, risks, and possible molecular mechanisms of ivermectin, which is suggested to be an effective treatment option, are discussed within the framework of the pharmacokinetic and toxicokinetic properties of the drug.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

To date, no effective treatment has been found against coronaviruses (CoVs), which have re-emerged with severe acute respiratory syndrome CoV-2 (SARS-CoV-2) and have a high potential for disease in humans as well as domestic and wild animal species. The investigation of treatment options to combat this virus, which has a pandemic character with its high morbidity and mortality rate, is a multidisciplinary research subject. In this context, the drug repositioning has come to the agenda in the fight against SARS CoV-2, which is the current subject. However, despite the superior characteristics of drug options other than rational usage purposes such as easy accessibility and rapid transfer to the field, the lack of evaluations for their efficacy and safety may lead to misleading. In this review, the applicability, risks, and possible molecular mechanisms of ivermectin, which is suggested to be an effective treatment option, are discussed within the framework of the pharmacokinetic and toxicokinetic properties of the drug.

Abstract

Şiddetli akut solunum sendromu koronavirüs-2 (SARS-CoV-2) ile yeniden gündeme gelen, evcil ve yabani hayvan türlerinin yanı sıra insanlarda da hastalık yapabilme potansiyeli yüksek olan CoV karşı günümüze değin etkin bir tedavi yöntemi bulunamamıştır. Yüksek morbidite ve mortalite oranı ile pandemik bir karakter kazanan bu virüsle mücadele amacıyla tedavi seçeneklerinin araştırılması multidisipliner bir araştırma konusudur. Bu kapsamda, güncel konu niteliğinde olan SARS-CoV-2 ile mücadelede ilaçların yeniden konumlandırma çalışmaları gündeme gelmiştir. Ancak rasyonel kullanım amaçlarının dışındaki ilaç seçeneklerinin, kolay ulaşılabilirlik ve hızla uygulamaya aktarılabilir olmaları gibi üstün özelliklerine rağmen, etkinlik ve güvenilirliklerine yönelik değerlendirmelerin yapılmamış olması yanlış yönlendirmelere yol açabilmektedir. Bu derlemede, etkin bir sağaltım seçeneği olabileceği ileri sürülen ivermektinin SARS-CoV-2 tedavisinde kullanılabilirliği, riskleri ve olası moleküler mekanizmalar, ilacın farmakokinetik ve toksikokinetik özellikleri çerçevesinde ele alınmıştır.

🔖

Bu Makaleye Atıf Yap

KESMEN, M., ANLAŞ, C., BAKIRELİ, T., GÜLER, E. M. (2020). COVID-19: Ivermectin; Molecular Mechanisms, Limitations, Suggestions. Bezmiâlem Science, Cilt: 8 - Sayı: 3, 39–43. https://ajindex.com/articles/406556

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. İnal S. Middle East Respiratory Syndrome-Coronavirus (MERSCoV) Enfeksiyonu: Okmeydanı Tıp Dergisi 2016;32(Ek sayı):37-45
  2. Microbiology Book Online, Viroloji Bölüm 25, Koronavirüsler, Soğuk Algınlığı ve SARS, Availeble from: https://www.microbiologybook. org/Turkish-virology/virolchapter25turk.htm 3. TÜBİTAK, Bilim ve Teknik Dergisi, Küresel Kabus, Availeble from: https://tubitak.gov.tr/sites/default/files/18842/bilim_ve_teknik_ coronavirus_hakkinda.pdf 4. Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and SARS-COV-2. Turkish Journal of Medical Sciences.
  3. International Committee on Taxonomy of Viruses (ICTV), Naming the 2019 Coronavirus 2020. Availeble from: https://talk.ictvonline. org/ 6. World Health Organisation, Naming the coronavirus disease (COVID-19) and the virus that causes it, 2020. Availeble from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/ technical-guidance/naming-the-coronavirus-disease-(covid-2019)- and-the-virus-that-causes-it 7. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: Progress, challenges and recommendations. Içinde Nat Rev Drug Discov 2018;1:41-58
  4. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19 2020. Available from: https://www.cdc. gov/coronavirus/2019-ncov/hcp/therapeutic-options.html 9. T.C. Sağlık Bakanlığı COVID-19 (SARS-CoV-2 ENFEKSİYONU) REHBERİ 2020. Available from: https://covid19bilgi.saglik.gov.tr/ depo/rehberler/COVID-19_Rehberi.pdf?type=file 10. World Health Organisation Off-label use of medicines for COVID-19 2020. Available from: https://www.who.int/news-room/ commentaries/detail/off-label-use-of-medicines-for-covid-19 11. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:104787. https://doi.org/10.1016/j. antiviral.2020.104787 12. U.S.National Institute of Health, Clinical Trials, 2020. Available from: https:// clinicaltrials. gov/ct2/ results?cond= COVID&term= ivermectin&cntry= &state=&city= &dist= &Search=Search 13. U.S. Food and Drug Administration, Letter to Stakeholder, 2020, Available from:
  5. Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest,